Skip to main navigation Skip to search Skip to main content

PROTECT: PRV-031-001-A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab

Project: Research

Project Details

StatusActive
Effective start/end date06/10/19 → 12/31/26

Funding

  • Parexel International LLC: $599,356.32